Company Filing History:
4 out of 636 
3 out of 2,109 
3 out of 2,611 
Years Active: 1997-2003
Title: Richard R Behringer: Innovator in Hemoglobin Synthesis
Introduction
Richard R Behringer is a prominent inventor based in Philadelphia, PA (US). He has made significant contributions to the field of biotechnology, particularly in the synthesis of functional human hemoglobin and other proteins. With a total of 4 patents, his work has advanced the understanding and application of genetic engineering in transgenic animals.
Latest Patents
Behringer's latest patents include groundbreaking inventions such as the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human mammals. This invention is based on the discovery that two of the five hypersensitivity sites of the β-globin locus are sufficient to achieve high-level expression of human α- or β-globin transgenes. Another notable patent involves novel recombinant nucleic acid vectors that can produce α-globin and other proteins in quantity within the red blood cells of transgenic animals or erythroid cell cultures. These vectors comprise major DNase I hypersensitivity sites associated with the β-globin locus, allowing for the creation of transgenic animals that express human hemoglobin in their erythroid tissues.
Career Highlights
Throughout his career, Richard R Behringer has worked with esteemed organizations such as the UAB Research Foundation and the University of Washington. His research has significantly impacted the field of genetic engineering and biotechnology, paving the way for advancements in medical applications.
Collaborations
Behringer has collaborated with notable colleagues, including Tim M Townes and Thomas M Ryan. These partnerships have further enriched his research and contributed to the success of his innovative projects.
Conclusion
Richard R Behringer's contributions to the field of biotechnology, particularly in hemoglobin synthesis, highlight his role as a leading inventor. His patents and collaborations reflect a commitment to advancing scientific knowledge and applications in genetic engineering.